Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 515.00 GBp
Change Today +20.25 / 4.09%
Volume 502.1K
GWP On Other Exchanges
Symbol
Exchange
London
OTC US
NASDAQ GM
Frankfurt
NASDAQ GM
Stuttgart
As of 11:35 AM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

gw pharmaceuticals plc (GWP) Snapshot

Open
489.00 GBp
Previous Close
494.75 GBp
Day High
530.50 GBp
Day Low
489.00 GBp
52 Week High
03/17/15 - 580.00 GBp
52 Week Low
04/16/14 - 205.00 GBp
Market Cap
1.2B
Average Volume 10 Days
472.7K
EPS TTM
-0.07 GBp
Shares Outstanding
236.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GW PHARMACEUTICALS PLC (GWP)

gw pharmaceuticals plc (GWP) Details

GW Pharmaceuticals plc, a biopharmaceutical company, together with its subsidiaries, engages in discovering, developing, and commercializing cannabinoid prescription medicines. It operates in three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The company primarily offers Sativex, an oromucosal spray for the treatment of multiple sclerosis symptoms, cancer pain, and neuropathic pain. It also focuses on the Phase III clinical development program of Sativex for use in the treatment of cancer pain. In addition, the company’s product pipeline includes an orphan childhood epilepsy program, as well as other product candidates in Phase I and II clinical development for the treatment of glioma, ulcerative colitis, type-2 diabetes, and schizophrenia. It has a strategic alliance with Otsuka Pharmaceutical Co., Ltd. The company operates in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Salisbury, the United Kingdom.

294 Employees
Last Reported Date: 02/4/15
Founded in 1998

gw pharmaceuticals plc (GWP) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: 567.8K GBP
Founder, Executive Chairman and Chairman of N...
Total Annual Compensation: 696.1K GBP
Chief Financial Officer, Company Secretary an...
Total Annual Compensation: 389.8K GBP
Chief Operating Officer and Executive Directo...
Total Annual Compensation: 421.8K GBP
Research & Development Director and Executive...
Total Annual Compensation: 475.3K GBP
Compensation as of Fiscal Year 2014.

gw pharmaceuticals plc (GWP) Key Developments

GW Pharmaceuticals plc Presents at Merrill Lynch Smid Cap Conference 2015, Mar-18-2015 08:00 AM

GW Pharmaceuticals plc Presents at Merrill Lynch Smid Cap Conference 2015, Mar-18-2015 08:00 AM. Venue: Four Seasons Hotel, 200 Boylston street, Boston, Massachusetts, United States. Speakers: Justin D. Gover, Chief Executive Officer, Managing Director and Executive Director.

GW Pharmaceuticals plc Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015

GW Pharmaceuticals plc Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015 . Venue: JW Marriott Essex House, 160 Central Park South, b/w 6th & 7th Avenue, New York, New York, United States.

GW Pharmaceuticals plc Reports Consolidated Earnings Results for the First Quarter Ended December 31, 2014

GW Pharmaceuticals plc reported consolidated earnings results for the first quarter ended December 31, 2014. For the quarter, the company reported revenue of £8.0 million ($12.4 million) compared to £7.5 million for the three months ended 31 December 2013. Loss was £3.4 million ($5.3 million) or 1.4 pence per basic and diluted share compared to £2.8 million 1.6 pence per basic and diluted share for the three months ended 31 December 2013. The company reported operating loss of £4.5 million compared to £3.5 million, loss before tax of £4.5 million compared to £3.5 million, net cash outflow from operating activities of £6.2 million compared to £2.4 million and purchases of property, plant and equipment of £5.9 million compared to £0.7 million for the last year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GWP:LN 515.00 GBp +20.25

GWP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cannabis Science Inc $0.04 USD +0.0011
Medical Marijuana Inc $0.10 USD -0.0025
PharmaCyte Biotech Inc $0.14 USD +0.001
View Industry Companies
 

Industry Analysis

GWP

Industry Average

Valuation GWP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 36.5x
Price/Book 7.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 36.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GW PHARMACEUTICALS PLC, please visit www.gwpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.